| Patent application number | Description | Published |
|---|
| 20080207952 | NOVEL THERAPEUTIC APPLICATIONS OF NATURAL POLY ISOPRENYLATED BENZOPHENONE DERIVATIVES AS DRUGS/MEDICAMENTS - Disclosed are novel therapeutic properties including (i) anti-microbial activity towards acne causing bacteria; (ii) Strong anti-matrix metalloproteinase activity; and (iii) anti-cyclooxygenase 2 activities of naturally occurring poly isoprenylated benzophenone derivatives. Also disclosed are novel applications of naturally occurring polyisoprenylated benzophenones as drugs/medicaments for treating or preventing the pathological symptoms associated with (i) acne, boils and pimples; (ii) enhanced activity of matrix metalloproteinase enzyme; and (iii) enhanced activity of cyclooxygenase-2 enzyme. | 08-28-2008 |
| 20080226571 | Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin - A composition based on labdane-diterpenoids that provides better photo protection against both UV A and UV B radiations in the HaCaT human keratinocyte cell lines is disclosed. The composition comprises 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one alone and in combination with 6β-acetoxy-8,13-epoxy-1α,7β,9α-trihydroxylabd-14-en-11-one and/or 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one. The composition protects the cells of the skin from harmful UV A and UV B rays through synergistic mechanisms with utility as a safe long-term cosmetic solution for preventing UV-induced skin damage and to induce sunless tanning. Additionally, the composition enhances melanogenesis in B16F1 mouse melanoma cells acting as tanning inducers/accelerators both in the presence or absence of sunlight. Elevation of melanogenesis confers additional protection against UV-induced skin damage. | 09-18-2008 |
| 20080241285 | Compositions and Methods to Treat Alopecia - Disclosed is a topical composition comprising therapeutically effective amounts of solubilized labdane diterpenoids in combination with freeze dried liquid endosperm of | 10-02-2008 |
| 20080255377 | Processes for the Manufacture of Chiral and Racemic Forms of 3-Aminotetrahydrofurans, Their Salts and Derivatives - A novel process for the synthesis of (S)-3-Amino-tetrahydrofuran and (R)-3-Amino-tetrahydrofuran is described. The process is applicable for substituted chiral-3-aminotetrahydrofuran derivatives. | 10-16-2008 |
| 20080286387 | Standardized method for recovering enriched Indian date extract (IDE), properties of IDE and applications thereof - Disclosed are (i) a standardized method for the recovery of the polyphenolic contents from the seed coats of | 11-20-2008 |
| 20080286393 | Method for the enrichment of the polyphenolic contents from unripe fruit rinds of Terminalia belerica and uses thereof - An improved method for concentrating/enriching the polyphenolic contents from the dried, unripe fruit rinds of | 11-20-2008 |
| 20090169651 | ANTI-SKIN DAMAGE COMPOSITIONS WITH COMPLIMENTARY DUAL MODE OF ACTION - Disclosed are skin care compositions exerting a novel complementary dual mode of action in protecting the skin from day-to-day insults. The skin care compositions of the present invention comprise the extract from the liquid endosperm of | 07-02-2009 |
| 20090275665 | Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof - Disclosed are novel and enhanced anti-fungal properties of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione in comparison with the corresponding 95% pure form, said greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione being devoid of 5-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone and 3,5-Dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-heptane. The inventors disclose the uses of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as anti-fungal agents capable of inhibiting superficial and cutaneous mycoses in humans and treatment methods thereof. Also disclosed is the enhanced potential of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as compared to the corresponding 95% pure form against bacterial and fungal phytopathogens and applications thereof in agriculture. | 11-05-2009 |
| 20090318565 | Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof - Disclosed are novel compositions for the enhancement of the anti-oxidant potential of natural or metabolite hydrogenated (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione derivatives. It was discovered that the antioxidant potential of hydrogenated curcuminoids was highly enhanced when a closely structurally related 1,7-Bis(4-hydroxyphenyl)-3,5-heptanedione, exhibiting unexpectedly pro-oxidant properties, was removed from the compositions. | 12-24-2009 |
| 20100034758 | Peptides Modified with Triterpenoids and Small Organic Molecules: Synthesis and use in Cosmeceuticals - The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient. | 02-11-2010 |
| 20100034762 | Novel enrichment methods for gallic acid esters including 1-O-galloy1-bata-D-glucose and mucic acid gallates medicaments, therapeutic applications and methods of treatment thereof - Improved methods to prepare aqueous extracts of gallic acid esters including 1-O-galloyl-β- | 02-11-2010 |
| 20100062989 | OPTIMAL BIOLOGICAL MARKER FOR THE BIOLOGICAL POTENCY OF Emblica Officinalis Gaertn. (AMLA) FRUIT-METHODS AND PRODUCTS THEREOF - Disclosed is the most optimal biomarker for the BIOLOGICAL POTENCY of | 03-11-2010 |
| 20100075360 | UV BASED CELL VIABILITY AS AN INDICATOR OF SUN PROTECTION FACTOR AND METHODS OF MEASUREMENT THEREOF - Disclosed is a simple method of determining SPF based on the staining pattern of viable cells like mouse fibroblasts and human keratinocytes after exposure to ultraviolet radiations. The method provides results comparable to the standard methods of SPF measurement using human subjects. | 03-25-2010 |
| 20100076069 | FORSKOLIN DOSING REGIMEN IN OPEN ANGLE GLAUCOMA AND PATIENT COMPLIANCE METHODS THEREOF - Disclosed is an optimal dosing regimen for forskolin to ensure the most optimal pharmacokinetic/pharmacodynamic responses desired in the therapeutic management of open angle glaucoma. The optimal dosing regimen involves the ocular application of 2% forskolin solubilized using randomly-methylated beta-cyclodextrins one drop once a day to patients requiring therapy for open angle glaucoma. Also disclosed are methods of promoting patient compliance, in particular geriatric and pediatric patient compliance during the therapeutic management of glaucoma using an optimal dosing regimen for forskolin to ensure the best pharmacokinetic/pharmacodynamic effects, devoid of systemic side-effects encountered with the currently used beta-blockers or prostaglandins. | 03-25-2010 |
| 20100120911 | PRESERVATIVE SYSTEM FOR COSMETIC FORMULATIONS - Disclosed is a novel method for preserving cosmetic/personal care formulations through a two component preservative system, said system comprising (a) Component I which functions to eliminate the existing microbial contamination load in a natural cosmetic formulation base through an optimized pasteurization method that avoids deep freezing; and (b) Component II that includes the step of adding synergistic blends of fractionated essential oils, extracts and isolated compounds to the pre-pasteurized cosmetic base obtained through the method of component I, wherein the synergistic blends sustain the effects of pasteurization through anti-microbial and anti-oxidant effects, said anti-oxidant effects enhancing further the anti-microbial effects by virtue of inhibiting lipid per oxidation that facilitates the undue proliferation of microbe. | 05-13-2010 |
| 20100204339 | Orally Bioavailable Stilbenoids- Compositions and Therapeutic Applications Thereof - Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy- 3,4′-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3′,5′, 6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed. | 08-12-2010 |
| 20100204340 | ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF - A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4′-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 and 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I and (ii) 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed. An additional embodiment, also discloses the enhanced anti-Propionibacterium acnes activity of 3,5-dimethoxy-3,4′-dihydroxystilbenes represented by STR#I and compositions thereof. | 08-12-2010 |
| 20100240767 | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof - Disclosed is the cosmeceutical potential of 3,5-dimethoxy-4′-hydroxystilbene in terms of its melanogenesis inhibitory and photo protective activities. Also disclosed does a topical melanogenesis inhibitory composition comprising 0.01 to 50% by weight of 3,5-dimethoxy-4′-hydroxystilbene. | 09-23-2010 |
| 20110033565 | Protective Compositions for Dermal Papilla Cells - Disclosed are novel protective compositions for dermal papilla cells. In an embodiment the protective compositions of the present invention comprise 0.25% w/w or above of compositions comprising at least 10% w/w and above of 1-O-galloyl-β-D-glucose (β-glucogallin). In an embodiment, the said protective composition additionally comprises 50% to greater than 50% gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid. In another embodiment the invention also encompasses synergistic protective compositions comprising the said protective compositions and 0.5% concentrate of liquid endosperm of | 02-10-2011 |
